Keywords: b-ms, zerit, overtakes, glaxo, zidovudine, bristol-myers, squibb

B-MS' Zerit Overtakes Glaxo's Zidovudine

Article | 30 January 1998

Bristol-Myers Squibb reports that its HIV/AIDS treatment Zerit(stavudine) has overtaken Glaxo Wellcome's Retrovir (zidovudine; AZT) as the most ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bristol-Myers Squibb

Go to company listing

Related Drugs

Retrovir

Zidovudine

Stavudine

Zerit

Combivir

Go to drug listing